Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.
2026 · 2nd Quarter (Apr 1 - June 30)
BRAINFUTURES
Filed by HOOPER, LUNDY & BOOKMAN, P.C..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- HOOPER, LUNDY & BOOKMAN, P.C.
- Client
- BRAINFUTURES
- Filing UUID
- 1516d514-a3b0-40fb-ba90-4647315b5dc3
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.
FY2027 budget related to psychedelic therapies for treatment of mental health and substance use disorders.
H.R.2623 - Innovative Therapies Centers of Excellence Act of 2025, S. 4220 - Veterans Health Administration Novel Therapeutics Preparedness Act.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.